Physical and Enzymatic Perturbation of the Architecture of the Tunica media Destroys its Inherent Thromboresistance

Summary

The media layer of the arterial cryo-cross sections, is defective for vWf-dependent platelet adhesion. Exposure of the same layer by stripping off the most inner portions of the vessel wall results in a highly thrombogenic surface. Stripping or balloon dilation was applied to porcine arteries prior to functional assays. Cryosections of treated or untreated arteries were perfused with porcine blood at 3350 s-1 and platelet deposition was detected by indirect immunofluorescence. Following balloon dilation, vWf-dependent platelet deposition increased; covering 9.08 ± 1.36% of the total media surface area, this value for untreated vessels was 0.88 ± 0.14%. A 10-fold increase was also found in the binding of vWf-coated fluorescent beads to the media. In addition to mechanical procedures, treatment by serine-proteases like trypsin, chymotrypsin and proteinase 3, or by chondroitinase ABC, but not by heparitinase also resulted in a 7-10-fold increase in platelet coverage over the media. Collagen in the media may be complexed with another vessel wall component shielding the vWf-binding sites. Mechanical or biochemical processes unmask these sites, and increase the thrombogenicity of the vessel wall.

Keywords

Vascular media - von Willebrand factor - platelets - proteoglycan - collagen

• References

• 1 Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67 (06) 594-9.
• 2 Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem 1987; 262 (28) 13835-41.
• 3 Mazzucato M, Spessotto P, Masotti A, De Appollonia L, Cozzi MR, Yoshioka A. et al. Identification of domains responsible for von Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow. J Biol Chem 1999; 274 (05) 3033-41.
• 4 Sawada Y, Fass DN, Katzmann JA, Bahn RC, Bowie EJ. Hemostatic plug formation in normal and von Willebrand pigs: the effect of the administration of cryoprecipitate and a monoclonal antibody to Willebrand factor. Blood 1986; 67 (05) 1229-39.
• 5 Hovig T, Stormorken H. Ultrastructural studies on the platelet plug formation in bleeding time wounds from normal individuals and patients with von Willebrand’s disease. Acta Pathol Microbiol Scand [A] 1974; (248) 105-22.
• 6 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate–dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier syndrome. J Lab Clin Med 1978; 92 (05) 750-64.
• 7 Houdijk WP, Sakariassen KS, Nievelstein PF, Sixma JJ. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest 1985; 75 (02) 531-40.
• 8 Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I. A model of deep vessel injury. Influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation 1988; 78 (06) 1431-42.
• 9 van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HF, Connolly TM, de Groot PG. et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93 (02) 615-32.
• 10 Fass D, Shi C, Specks U. Von Willebrand dependent binding of platelets to artery wall. Circulation 1995; (Suppl. 92) I-804.
• 11 Komorowicz E, McBane RD, Charlesworth J, Fass DN. Reduced high shear platelet adhesion to the vascular media: defective von Willebrand factor binding to the interstitial collagen. Thromb Haemost 2002; 87 (03) 763-70.
• 12 Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 1991; 78 (02) 423-34.
• 13 Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH. et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99 (14) 1780-7.
• 14 Steele PM, Chesebro JH, Stanson AW, Holmes Jr. DR, Dewanjee MK, Badimon L. et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57 (01) 105-12.
• 15 Olson JD, Brockway WJ, Fass DN, Bowie EJ, Mann KG. Purification of porcine and human ristocetin-Willebrand factor. J Lab Clin Med 1977; 89 (06) 1278-94.
• 16 Katzmann JA, Mujwid DK, Miller RS, Fass DN. Monoclonal antibodies to von Willebrand's factor: reactivity with porcine and human antigens. Blood 1981; 58 (03) 530-6.
• 17 Bowie EJ, Fass DN, Katzmann JA. Functional studies of Willebrand factor using monoclonal antibodies. Blood 1983; 62 (01) 146-51.
• 18 Takami H, Nichols WL, Kaese SE, Miller RS, Katzmann JA, Bowie EJ. Monoclonal antibodies against porcine platelet membrane glycoproteins Ib and IIb/IIIa. Blood 1988; 72 (05) 1740-7.
• 19 Lindmark R, Thoren-Tolling K, Sjoquist J. Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J Immunol Methods 1983; 62 (01) 1-13.
• 20 Hovingh P, Linker A. The enzymatic degradation of heparin and heparitin sulfate. 3. Purification of a heparitinase and a heparinase from flavobacteria. Journal of Biological Chemistry 1970; 245 (22) 6170-5.
• 21 Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102 (04) 522-35.
• 22 Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94 (01) 172-8.
• 23 Shekhonin BV, Domogatsky SP, Muzykantov VR, Idelson GL, Rukosuev VS. Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. Coll Relat Res 1985; 05 (04) 355-68.
• 24 Morton LF, Barnes MJ. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. Atherosclerosis 1982; 42 (01) 41-51.
• 25 Wagner DD, Urban-Pickering M, Marder VJ. Von Willebrand protein binds to extracellular matrices independently of collagen. Proc Natl Acad Sci USA 1984; 81 (02) 471-5.
• 26 de Groot PG, Ottenhof-Rovers M, van Mourik JA, Sixma JJ. Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest 1988; 82 (01) 65-73.
• 27 Sawada Y, Sheetz MP. Force transduction by Triton cytoskeletons. J Cell Biol 2002; 156 (04) 609-15.
• 28 Raspanti M, Alessandrini A, Ottani V, Ruggeri A. Direct visualization of collagen-bound proteoglycans by tapping-mode atomic force microscopy. J Struct Biol 1997; 119 (02) 118-22.
• 29 Wight TN. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 09 (01) 1-20.
• 30 Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-52.
• 31 Poole AR, Webber C, Pidoux I, Choi H, Rosenberg LC. Localization of a dermatan sulfate proteoglycan (DS-PGII) in cartilage and the presence of an immunologically related species in other tissues. J Histochem Cytochem 1986; 34 (05) 619-25.
• 32 Voss B, Glossl J, Cully Z, Kresse H. Immunocytochemical investigation on the distribution of small chondroitin sulfate-dermatan sulfate proteoglycan in the human. J Histochem Cytochem 1986; 34 (08) 1013-9.
• 33 Snow AD, Bolender RP, Wight TN, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137 (02) 313-30.
• 34 Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144 (05) 962-74.
• 35 Vogel KG, Paulsson M, Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 1984; 223 (03) 587-97.
• 36 Uldbjerg N, Danielsen CC. A study of the interaction in vitro between type I collagen and a small dermatan sulphate proteoglycan. Biochem J 1988; 251 (03) 643-8.
• 37 Neame PJ, Kay CJ, McQuillan DJ, Beales MP, Hassell JR. Independent modulation of collagen fibrillogenesis by decorin and lumican. Cell Mol Life Sci 2000; 57 (05) 859-63.
• 38 Savage B, Ginsberg MH, Ruggeri ZM. Influence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flow. Blood 1999; 94 (08) 2704-15.
• 39 Birk DE, Fitch JM, Babiarz JP, Doane KJ, Linsenmayer TF. Collagen fibrillogenesis in vitro: interaction of types I and V collagen regulates fibril diameter. J Cell Sci 1990; 95 (04) 649-57.
• 40 Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997; 136 (03) 729-43.
• 41 Kauhanen P, Kovanen PT, Lassila R. Coimmobilized native macromolecular heparin proteoglycans strongly inhibit platelet-collagen interactions in flowing blood. Arterioscler Thromb Vasc Biol 2000; 20 (11) E113-9.
• 42 Olsson E, Asko-Seljavaara S, Lassila R. Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses. Thromb Haemost 2002; 87 (02) 245-51.
• 43 Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 2000; 97 (12) 6722-7.